11.18.25 -- Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics' Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D.

Policy, trade, and security pressures are reshaping global biologics manufacturing. Forward-looking companies are onshoring critical programs to mitigate risks to supply chains, IP, and regulatory timelines.

See how Codex HiCap RNA Polymerase supports the production of high-performance synthetic mRNA, paving the way for next-generation mRNA therapies.

Learn how AI is transforming the biomanufacturing industry and how partnerships between pharmaceutical companies and academic institutions are poised to set the new standard.

Learn how next-generation workflows are being developed to streamline iPSC manufacturing, enhance differentiation strategies, and overcome the hurdles of scalability and consistency.

Delve into the world of scaling decisions with insights from biopharma developers and a CDMO. Learn about their mutual interest in achieving successful scale-up and strategies for avoiding common pitfalls.

This panel session features a decade-long story of partnership in bringing two life-changing gene therapies to market successfully in 2022.

Learn how to navigate decision-making at critical steps and find solutions to key challenges in process development and scale-up to expedite oncolytic virus programs.

Hear experts discuss the latest trends in antibody-drug conjugate (ADC) discovery and development and how next-generation pipelines are being shaped by payload and linker-chemistry innovations.

Adopt next-generation, physiologic T cell activation strategies to enable faster, more consistent, and scalable CAR-T manufacturing that improves expansion, persistence, and patient access.

Conducted alongside the Faculty of Medicine at Palacky University and supported by the Technology Agency of the Czech Republic, this project focused on translating research into a viable medicinal product.

Delve into how cloud-based systems and unified data platforms are transforming biomanufacturing by enhancing efficiency, ensuring quality, and accelerating the delivery of complex therapies to market.

Learn how an approach with modular N-1 perfusion strategies shortens seed train timelines and reduces facility strain — enabling upstream processes that scale efficiently and reliably for commercial manufacturing.

The dynamic growth and pace of change observed in novel mAb formats and cell and gene therapies emphasizes that biomanufacturing innovation is essential to deliver scale, speed, and sustainability.